Source: Annual Congress 2001 - Mechanisms of airway inflammation in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. A. Dawkins, A. T. Hill, D. L. Bayley, R. A. Stockley (Birmingham, United Kingdom). Effect of danazol on acute phase reactants in patients with PiM, PiMZ and PiZ phenotypes for alpha-1-antitrypsin deficiency. Eur Respir J 2001; 16: Suppl. 31, 1703

Member's Comments

No comment yet.

Related content which might interest you: Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006 Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD. Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Erythrocyte abnormalities in alpha-1-antitrypsin deficiency (AATD) patients Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009 COPD in individuals with the PiMZ alpha-1 antitrypsin genotype Source: Eur Respir Rev, 26 (146) 170068; 10.1183/16000617.0068-2017 Year: 2017 Rare SERPINA1 allele Mwhitstable in patients with Alpha1-antitrypsin deficiency Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency Year: 2019 Characterization of a population of alpha1-antitrypsin deficient (A1ATD) patients Source: Annual Congress 2008 - COPD Year: 2008 GSTP1 polymorphisms in patients with COPD and alpha-1 antitrypsin deficiency Source: Eur Respir J 2003; 22: Suppl. 45, 384s Year: 2003 Young adult with inherited PiMZ alpha-1-antitrypsin deficiency (A1ATD)-related bronchiectasis: characteristic of blood neutrophils and A1AT protein Source: International Congress 2016 – Translational studies in lung disease Year: 2016 Mortality of patients with emphysema and alpha-1-antitrypsin deficiency of Pi Z phenotype Source: Eur Respir J 2001; 18: Suppl. 33, 25s Year: 2001 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Inhibitory profiles of alpha-1-antitrypsin from PiZ & PiSZ individuals and implications for tissue destruction in emphysema Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010 Severe alpha-1-antitrypsin deficiency (A1ATD) caused by Q0Ourém mutation: A clinical characterization Source: Annual Congress 2010 - Genetics of obstruction Year: 2010 Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Bronchiectasis in alpha1-antitrypsin deficiency Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019 Clinical consequences and longitudinal outcomes in PiMZ heterozygous a1-antitrypsin deficiency smokers from SPIROMICS Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021 Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020 Clinical features of alpha one antitrypsin deficiency in COPD Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 A new SERPINA-1 missense mutation associated with alpha-1 antitrypsin deficiency and bronchiectasis. Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017